Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $3.66 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.